Brief Report: Updated Efficacy and Safety Data From an Integrated Analysis of Entrectinib in Locally Advanced/Metastatic ROS1 Fusion-Positive Non-Small-Cell Lung Cancer

Clin Lung Cancer. 2024 Mar;25(2):e81-e86.e4. doi: 10.1016/j.cllc.2023.12.001. Epub 2023 Dec 7.
No abstract available

Keywords: First-line treatment; Intracranial efficacy; NSCLC; Tyrosine kinase inhibitor.

Publication types

  • Case Reports

MeSH terms

  • Benzamides*
  • Carcinoma, Non-Small-Cell Lung* / drug therapy
  • Carcinoma, Non-Small-Cell Lung* / genetics
  • Carcinoma, Non-Small-Cell Lung* / pathology
  • Humans
  • Indazoles*
  • Lung Neoplasms* / drug therapy
  • Lung Neoplasms* / genetics
  • Lung Neoplasms* / pathology
  • Protein Kinase Inhibitors / adverse effects
  • Protein-Tyrosine Kinases / genetics
  • Proto-Oncogene Proteins / genetics

Substances

  • entrectinib
  • Protein-Tyrosine Kinases
  • Proto-Oncogene Proteins
  • Protein Kinase Inhibitors
  • ROS1 protein, human
  • Benzamides
  • Indazoles